Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhimeng Biopharma Closes $35 Million Funding for Trials of HBV Therapy

publication date: Nov 13, 2020

Shanghai Zhimeng Biopharma closed a $35 million Series A round to support clinical trials of its novel hepatitis B virus nucleocapsid inhibitor and other products. Zhimeng started a US-based Phase I dose escalation study of ZM-H1505R, its lead HBV therapy, earlier this year. Zhimeng develops treatments for chronic hepatitis B infection and CNS therapies for stroke, epilepsy and other neurological disorders. The A round was led by Trinity Innovation Fund and included SDIC, Oceanpine Healthcare Fund and Photon Fund. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital